Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction

Clinical Kidney Journal

Volumn 6, Issue 1, 2013, Pages 55-62

  Waldum, Bård ^a,b   Stubnova, Viera ^b   Westheim, Arne S ^b   Omland, Torbjørn ^a,c   Grundtvig, Morten ^d   Os, Ingrid ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d INNLANDET HOSPITAL TRUST   (Norway)

Author keywords

B type natriuretic peptides; heart failure; prognostic marker; renal dysfunction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE REGISTRY; FEMALE; HEART FAILURE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 84873380924     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs174     Document Type: Article

References (29)

1. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-1787
2. Masson S, Latini R, Anand IS et al. Direct comparison of Btype natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-1538
3. Alehagen U, Lindstedt G, Levin LA et al. Risk of cardiovascular death in elderly patients with possible heart failure. Btype natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 2005; 100: 125-133
4. Dhar S, Pressman GS, Subramanian S et al. Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence. Postgrad Med J 2009; 85: 299-302
5. van Kimmenade RR, Januzzi JL Jr., Bakker JA et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884-890
6. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis 2003; 41: 571-579
7. Martinez-Rumayor A, Richards AM, Burnett JC et al. Biology of the natriuretic peptides. Am J Cardiol 2008; 101: 3-8
8. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
9. Astor BC, Hallan SI, Miller ER III et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167: 1226-1234
10. DeFilippi CR, Fink JC, Nass CM et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44
11. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-620
12. de Silva R, Nikitin NP, Witte KK et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-581
13. Waldum B, Westheim AS, Sandvik L et al. Renal function in outpatients with chronic heart failure. J Card Fail 2010; 16: 374-380
14. McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009
15. Grundtvig M, Gullestad L, Hole T et al. Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure results from the Norwegian heart failure registry. Eur J Cardiovasc Nurs 2011; 10: 1044-49
16. Yandle T, Fisher S, Espiner E et al. Validating aminoterminal BNP assays: a word of caution. Lancet 1999; 353: 1068-1069
17. Katz MH. Assumptions of multiple linear regression, multiple logistic regression, and propotional hazards analysis. Multivariable Analysis. Cambridge, UK: Cambridge University Press, 2006; 38-67
18. Luchner A, Hengstenberg C, Lowel H et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46: 118-123
19. Gardner RS, Chong KS, O'Meara E et al. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Heart J 2007; 28: 3027-3033
20. van Kimmenade RR, Januzzi JL Jr., Baggish AL et al. Aminoterminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621-1627
21. Richards M, Nicholls MG, Espiner EA et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47: 52-60
22. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005; 16: 469-477
23. Alehagen U, Lindstedt G, Eriksson H et al. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003; 49: 1337-1346
24. Takami Y, Horio T, Iwashima Y et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysisdependent CRF. Am J Kidney Dis 2004; 44: 420-428
25. Austin WJ, Bhalla V, Hernandez-Arce I et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-512
26. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003; 16: 101-105
27. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
28. Palazzuoli A, Gallotta M, Quatrini I et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 2010; 6: 411-418
29. McCullough PA, Neyou A. Comprehensive review of the relative clinical utility of B-type natriuretic peptide and N-terminal Pro-B-type natriuretic peptide assays in cardiovascular disease. Open Heart Fail J 2009; 2: 6-17